<table>
<thead>
<tr>
<th>Contents</th>
<th>Monthly Volume 12 Number 8 August 26, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FIELD OF VISION</strong></td>
<td></td>
</tr>
<tr>
<td>362</td>
<td>Oliver Wendell Holmes’ 1836 doctorate dissertation and his journey in medicine</td>
</tr>
<tr>
<td>Cohen SI</td>
<td></td>
</tr>
<tr>
<td><strong>OPINION REVIEW</strong></td>
<td></td>
</tr>
<tr>
<td>368</td>
<td>Classic Ehlers-Danlos syndrome and cardiac transplantation - Is there a connection?</td>
</tr>
<tr>
<td>Butler MG</td>
<td></td>
</tr>
<tr>
<td><strong>REVIEW</strong></td>
<td></td>
</tr>
<tr>
<td>373</td>
<td>Sympathetic nervous system activation and heart failure: Current state of evidence and the pathophysiology in the light of novel biomarkers</td>
</tr>
<tr>
<td>Borovac JA, D’Amario D, Bozic J, Glavas D</td>
<td></td>
</tr>
<tr>
<td><strong>MINIREVIEWS</strong></td>
<td></td>
</tr>
<tr>
<td>409</td>
<td>Forensic interrogation of diabetic endothelitis in cardiovascular diseases and clinical translation in heart failure</td>
</tr>
<tr>
<td>Thomas MC, Iyngkaran P</td>
<td></td>
</tr>
<tr>
<td><strong>ORIGINAL ARTICLE</strong></td>
<td>Retrospective Cohort Study</td>
</tr>
<tr>
<td>419</td>
<td>Impact of cardiologist intervention on guideline-directed use of statin therapy</td>
</tr>
<tr>
<td>Cassagnol M, Hai O, Sherali SA, D’Angelo K, Bass D, Zeltser R, Makaryus AN</td>
<td></td>
</tr>
<tr>
<td><strong>META-ANALYSIS</strong></td>
<td></td>
</tr>
<tr>
<td>427</td>
<td>Systematic review and meta-analysis of outcomes of anatomic repair in congenitally corrected transposition of great arteries</td>
</tr>
<tr>
<td>Chatterjee A, Miller NJ, Cribbs MG, Mukherjee A, Law MA</td>
<td></td>
</tr>
</tbody>
</table>
ABOUT COVER
Editorial board member of World Journal of Cardiology, Dr. Huang is a Professor of Cardiology at Shunde Hospital, Southern Medical University in Guangzhou, China. He is also an Honorary Senior Research Fellow at the George Institute for Global Health in Newton, Australia. Dr. Huang received his PhD in 2014 and became Chief Physician in the Cardiology Department of Shunde Hospital in 2018, a position he still occupies. His research interests include pathogenesis and therapeutics for hypertension, risk factors of cardiovascular disease, epidemiology of cardiovascular disease, and metabolic therapy for heart failure. As lead author, he has published more than 50 papers, in such respected journals as BMJ (3), Neurology (2), and BMC Medicine. The total citations for Dr Huang’s publications are up to 2000 and his H-index is 22 as of July, 2020. (L-Editor: Filipodia)

AIMS AND SCOPE
The primary aim of World Journal of Cardiology (WJC, World J Cardiol) is to provide scholars and readers from various fields of cardiology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJC mainly publishes articles reporting research results and findings obtained in the field of cardiology and covering a wide range of topics including acute coronary syndromes, aneurysm, angina, arrhythmias, atherosclerosis, atrial fibrillation, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure, hypertension, imaging, infection, myocardial infarction, pathology, peripheral vessels, public health, Raynaud’s syndrome, stroke, thrombosis, and valvular disease.

INDEXING/ABSTRACTING
The WJC is now abstracted and indexed in Emerging Sources Citation Index (Web of Science), PubMed, PubMed Central, Scopus, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (CSTJ), and Superstar Journals Database.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Jia-Hui Li; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ping Yan.
Forensic interrogation of diabetic endothelitis in cardiovascular diseases and clinical translation in heart failure

Merlin C Thomas, Pupalan Iyngkaran

Abstract

Diabetic heart disease (DHD) can be classified as a primary consequence from several pathophysiological manifestation of diabetes mellitus (DM) on cardiac tissues or secondarily in extracardiac tissues and is encountered as either primary or secondary complications of DM. Endothelitis is inflammation of the vascular endothelium and is likely to be seen in the majority of patients who start to manifest an end organ complication of DM in this case DHD. Diabetes is a leading cause for many cardiovascular syndromes and diseases including congestive heart failure (CHF) however much remains unknown about the transition from diagnosed DM to clinical state and the contribution of the various mechanical and counterregulatory systems in the manifested complaint. Diastolic heart failure or heart failure with preserved ejection fraction (DHF/HFpEF), accounts for half of all CHF presentations, has DM as a major contributor, however, there remain large gaps in clinical and pathophysiological understanding. This review aims to explore the microscopic aspects in diabetic endothelitis and provide a clinical link with context to HFpEF.

Key words: Cardiovascular disease; Diabetic heart disease; Diabetes mellitus; Diastolic heart failure; Endothelitis; Heart failure with preserved ejection fraction; Inflammation

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: We discuss the concept of diabetes mellitus and inflammation in the endothelium of blood vessels or “diabetic endothelitis”. The vascular endothelium permeates every organ in the body. Macro and microvascular inflammation in coronary and related arterial beds contributes to diabetic heart diseases such as congestive heart failure. Heart failure...
with preserved ejection fraction is an important and poorly understood condition. In this review we provide a basic science perspective and a clinical link to this problem.

**INTRODUCTION**

Basic sciences are the doorway for forensic analysis of clinical syndromes. Since the early community heart studies such as Framingham Heart Studies two clear delineations of congestive heart failure were observed, systolic heart failure where all cases had diastolic impairment and isolated heart failure where systolic function appeared preserved from all available diagnostic tools hence diastolic heart failure or Heart Failure with preserved Ejection Fraction (DHF/ HFpEF)\(^1\). The former is well studied however the latter still struggles from a fixed definition, aetiology, pathophysiology and diagnostic taxonomy and a single proven prognostic therapy\(^2\).

The bench will play a critical role in understanding this syndrome. Diabetes Mellitus (DM) and its common end organ complication of “endothelitis” are seen in all diabetic heart disease (DHD) and is a valid area to focus to identify a bedside link for HFpEF.

The vascular endothelium, that forms the lining of all blood and lymphatic vessels, is uniquely vulnerable to the effects of chronic or intermittent hyperglycaemia\(^3\). Being largely dependent on glycolytic metabolism for generating adenosine triphosphate rather than oxidative phosphorylation, the uptake of glucose into endothelial cells is not downregulated as ambient glucose levels rise. This means that increasing glycolytic flux increasingly generates toxic intermediates including reactive dicarbonyls and reactive oxygen species (ROS). This glucotoxicity, along with the additional impacts of lipotoxicity, endoplasmic reticulum (ER) stress, inflammasome activation, oxidative and shear stress in diabetes induce pathophysiological changes in the vascular endothelium that are best characterised as “endothel-it is”. These changes include increased adhesion and extravasation of leucocytes, production of chemokines/cytokines, exudation of plasma, altered vasomotor tone and haemostasis, endothelial senescence and apoptosis, endothelial to mesenchymal transition (EndoMT) and neo-angiogenesis that contribute not only to accelerated atherosclerosis but also the development of progression of heart failure in diabetes\(^3-6\) (Figure 1).

Moreover, although originally considered a consequence of hypertrophy and overload, HFpEF is increasingly viewed as a “microvascular” disorder driven by endothelitis\(^7\). In this paper, we explore the key inflammatory changes in the vascular endothelium and their potential role in DHD. We also provide a short hypothetical perspective of a contextual bedside translational strategy to advance a clinical focus for diabetic endothelitis (“diabetic endothelitis” is a term the authors use to describe endothelial injury associated with the chronic inflammatory milieu of diabetes. The exact proponents of the injury and its manifestations are the subject of this paper and ongoing works. Conventional vascular inflammation often associated with connective tissue diseases are well described. The endothelium itself is a component of the vasculature, is less describe in that sense. When endothelial function is altered the term “endothelial dysfunction” is used.).

**CELLULAR BASIS OF DIABETIC INFLAMMATION IN THE ENDOTHELIUM AND DYSFUNCTION**

*Endothelitis, leukocyte recruitment and infiltration*

Activation of the vascular endothelium plays a key initiating role in the leucocyte adhesion and the subsequent development of the nascent atherosclerotic plaque. Intrinsically, monolayer of endothelial cells forms a critical interface between circulating immune cells and the tissues of the body. The luminal expression of chemokines, like macrophage chemoattractant protein (MCP-1), attracts leucocytes,
Figure 1 Endothelitis is associated with a range of dysfunctional changes that contribute the development and progression of cardiovascular disease. EndoMT: Endothelial-mesenchymal transition; EPC: Endothelial progenitor cell.

which then roll, arrest and bind to an activated endothelium expressing adhesion molecules, including selectins, intercellular adhesion molecule (ICAM)-1, and vascular cell adhesion molecule (VCAM)-1, Junctional Adhesion Molecules (JAMs), P-selectin and E-selectin, and subsequently migrate into the sub-epithelium and beyond. Subepithelial macrophages become engorged with cholesterol creating lipid-laden macrophages known as foam cells, creating fatty streaks and eventually the necrotic core of atheromatous plaques after their cellular death. In diabetes, the rate at which circulating monocytes enter the atherosclerotic lesion is increased, while plaque regression is reduced\[8\]. The increased transit of activated inflammatory cells into the vessel wall in diabetes, not only leads to more atherosclerosis, but as a result, atherosclerosis is more complex, multivessel with more unstable plaque in diabetes. Diabetic heart failure in diabetes is also characterised by a leukocytic infiltration, including activated monocytes, T-cells and dendritic cells\[9,10\]. As with atherosclerosis, these cells largely originate in the bloodstream and therefore must bind to and cross an activated endothelium expressing adhesion molecules to reach the heart in a targeted way.

Endothelitis and endothelial dysfunction

Endothelial dysfunction is one end-result of the phenotypic changes associated with endothelitis. Although there are very many dysfunctional microvascular changes associated with endothelitis, the best characterised is an impairment of endothelium-dependent nitric oxide (NO)-mediated vasodilatation. In healthy vessels, increased shear stress triggers flow-mediated vasodilatation due to increased synthesis and release of NO, the principal regulator of vascular tone, that acts on underlying smooth muscle to relax blood vessels. In patients with diabetes, vaso-relaxation is significantly impaired or even paradoxically reversed. This is partly due to impaired formation of NO due to uncoupling of endothelial nitric oxide synthase and a decrease in tetrahydrobiopterin and L-arginine, the co-factor and the substrate, respectively, for NO synthesis. At the same time, the bioavailability of NO is reduced due to quenching by ROS and reactive dicarbonyls. In addition, elevated levels of asymmetric dimethylarginine, function as an endogenous competitive inhibitor of NO activity.

Endothelial dysfunction can be measured using invasive tests by selective infusion of acetylcholine into the epicardial coronary arteries. However, it is more commonly estimated using non-invasive testing, including flow-mediated dilation (FMD), low-flow-mediated constriction of the brachial artery measured by ultrasound, and peripheral arterial tonometry (EndoPAT) using the finger pulse wave amplitude in response to reactive hyperaemia. More recently, changes in endothelial-mediated blood flow can be identified using monitored by positron emission tomography. Each of these non-invasive are correlated with the results of invasive testing as well as future cardiac outcomes. However, each phenomenon is only partly NO determined. Moreover, none have a clear place in guiding treatment or prognosis in the clinic.

Compromised endothelium-dependent vasodilatation is thought to be an important contributor to increased myocardial ischemia in diabetes. In particular, myocardial ischemia in individuals with relatively normal epicardial coronary arteries (also known as microvascular angina) appears to be partly driven by impaired
endothelium-mediated vasomotion in the cardiac microvasculature. For example, 10-year data from the Women’s Ischemia Syndrome Evaluation (WISE) study, found that half of individuals undergoing angiography for investigation of chest pain, but found not to have obstructive coronary disease, had endothelial dysfunction\(^{[11]}\), and those that did had worse clinical outcomes. This is not simply an epiphenomenon, as abnormal vasomotion may also be observed before the development of atherosclerotic lesions or overt cardiovascular disease. For example, in individuals at moderate CV risk but without macrovascular disease, endothelial dysfunction is associated with an increased incidence of CV events\(^{[12]}\).

The role of microvascular ischemia/hypoxia in the pathogenesis of diabetic heart failure remains controversial. While there is a clear association between endothelial dysfunction and diastolic dysfunction in heart disease, this may simply be because of common risk factors (e.g., diabetes) rather than a linked pathogenesis. Certainly, reduced oxygen delivery impairs myocyte relaxation, especially in the setting of increased oxygen demands associated with increased intramyocardial tension. Chronic ischemia may lead to subclinical micro-scars replacing small foci of dead cardiomyocytes, that cumulatively result in myocardial stiffening. Endothelium-mediated control of the venous vascular tone is also important for the regulation of cardiac filling pressures.

### CONSEQUENCES OF ENDOTHELITIS

#### Endothelitis and increased vascular permeability

The best-known pathophysiological change associated with microvascular dysfunction in diabetes is the accompanying increase in vascular permeability. The healthy endothelium provides an effective semipermeable barrier that prevents the exudation of plasma contents despite high intravascular pressures. In hyperglycaemia, increased permeability and loss of endothelial barrier function, results in extravasation of circulating elements (e.g., large molecular weight proteins, lipoprotein particles, clotting factors) into the interstitial space and tissue oedema. This is simply observed as hard exudates in the retina or with increased albuminuria, both of which are strongly associated with and increased risk of cardiovascular events and heart failure. This is because impaired barrier functions in one site predict endothelial dysfunction at other sites (the so called “Steno hypothesis”).

Increased vascular permeability in diabetes is likely the functional end result of multiple pathophysiological changes in the endothelium including thinning and changes in the composition of the surface glycocalyx, rearrangements of cell-to-cell junctions (paracellular trafficking) and altered vesicular trafficking (transcytosis) associated with endothelitis. One of the most important regulators of barrier function is considered to be Vascular Endothelial Growth Factor (VEGF). The induction of VEGF in diabetes directly increases vascular permeability\(^{[13]}\). Outside of diabetes (e.g., in sepsis), loss of barrier function may also be partly VEGF-dependent.

#### Endothelitis, thrombo-resistance and fibrinolysis

A healthy endothelium creating an anticoagulant surface for blood flow that inhibits the formation of intraluminal clots (known as thromboresistance). By contrast, an inflamed endothelium is thrombogenic in a number of different ways. For example, endothelial dysfunction is associated with a reduction in expression of the membrane bound anticoagulant glycoprotein, thrombomodulin. At the same time, the release of soluble thrombomodulin is increased, leading to increased circulating levels in patients with diabetes, especially those with vascular complications. Indeed, soluble thrombomodulin levels in diabetes closely correlate with other markers of endothelitis, including circulating cytokines, oxidative stress markers, vascular permeability (e.g., albuminuria, retinal exudates) and impaired FMD. At the same time, an inflamed endothelium also liberates thrombogenic molecules including plasma factor VIII, von Willebrand factor, fibronectin, inhibitor of plasminogen activator type 1, and thrombospondin. Platelet aggregation is also enhanced in diabetes. Although a healthy endothelium produces anti-aggregants, including such as NO and PGI\(_2\), to attenuate this process as a negative feedback mechanism. However, both are reduced in the setting of endothelitis.

#### Endothelitis and vascular rarefaction

Compounding the obvious tissue hypoxia associated with diabetes, there is often a reduction in microvascular density (known as rarefaction or capillary dropout) that is
触发的内皮炎⑨。这种现象在糖尿病视网膜病变中描述得最为详尽，视网膜供血不足，导致视网膜细胞死亡，从而成为驱动组织缺氧和随后的病理性新生血管形成的因素。然而，在糖尿病性心脏中，内皮炎也导致毛细血管供血不足，与心室顺应性降低和增加左心室壁厚度有关⑩。尸检研究在个体间具体特征与心室功能障碍也证明微血管密度在心脏中更为严重⑩。在体内，心室功能障碍时密切相关的微血管密度在心脏中显著降低⑩。在每个案例中，心室功能障碍被认为是由炎症性变化导致，这些变化导致在不充分的新生血管/再生和增加相应的血管破坏/收缩比例导致心力衰竭和/或细胞死亡。

内皮细胞衰老是一种不可逆的表型转变，导致细胞周期停滞。它可以通过内皮炎症（例如，NF-κB的活化）以及在从促进炎症的促动脉粥样硬化的，和血管收缩性状态中增加的细胞因子的产生和表达为特征的内皮炎症（代表内皮炎）而发生，这反过来可能导致更多衰老⑪。暴露于高血糖水平也会引发内皮细胞衰老⑪。这种可能是通过一个数量的水平，包括细胞/DNA损伤由活性氧物种（例如，ROS，二羰基），端粒短化，线粒体损伤，氧化应激和血管收缩性状态内皮细胞衰老已经观察到。内皮细胞衰老也有可能促进动脉粥样硬化，血栓形成和粥样硬化斑块不稳定。此外，最近的研究也建议内皮细胞衰老也可能会在心脏衰竭发生。例如，在一个加速的模型中，由内皮细胞衰老触发的动脉粥样硬化，同时导致内皮细胞功能障碍也增加了⑪。此外，敲除内皮细胞p53可以预防内皮细胞衰老，以及心肌纤维化，导致被以下压力过载所致⑪。

内皮细胞衰老的最后阶段是细胞程序性死亡（细胞死亡）的内皮细胞。是否这种直接由细胞衰老或间接由于暴露于内皮炎性和氧化性损害在衰老的内皮细胞是不确定的。当然，细胞死亡可能也可以被独立于细胞衰老，特别是与内皮细胞衰老触发的细胞死亡由氧化应激，粘附的应力，抗血管生成Ⅱ，胆固醇和氧化应激。增加内皮细胞细胞死亡也被观察到在内皮细胞衰老覆盖不稳定的动脉粥样硬化斑块和在动脉粥样硬化的倾向区的内皮细胞。细胞死亡不仅会导致内皮细胞屏障功能的破坏，还可以触发细胞死亡。内皮细胞衰老的最终疾病也可能是自身免疫性的动脉粥样硬化以及内皮细胞衰老障碍。细胞滋养细胞和血小板。此外，从细胞死亡的细胞释放DNA，ATP，miRNA存在于细胞自由和微体中。来自细胞损伤的微体可以与周围内皮细胞沟通。内皮细胞衰老的这些微体可能是有用的内皮细胞衰老的标记，以及其对治疗的反应。

ENDOTHELIUM，MYOCARDIUM AND VASCULARITY

内皮炎和EndoMT

内皮细胞和EndoMT的中心参与者的纤维化是由成纤维细胞（图2）。这些可以由在局部的成纤维细胞和招募的前体细胞的活化引起。此外，炎症性的内皮细胞能够通过一种被称为内皮-间质性转变（EndoMT）的方式转变为成纤维细胞。的确，27%-35%的总成纤维细胞在心肌纤维化期间可能来自内皮细胞⑩。这个TGF-β1-依赖的细胞转化和其随后的脱落和迁移入的心脏间质导致增加了外源性细胞的新生血管形成和增加了纤维化蛋白质，导致了内皮细胞衰老的致动。内皮细胞衰老的这种TGF-β1-依赖的转化和其随后的脱落和迁移入的心脏间质导致了内皮细胞衰老①1。这个TGF-β1-依赖的转化和其随后的脱落和迁移入的心脏间质导致了内皮细胞衰老。当这些成纤维细胞从心肌细胞上激活，它们可以促进心肌细胞去分化，导致细胞死亡。在体内，从成纤维细胞释放的活性成纤维细胞可能在心肌细胞上激活，导致细胞死亡。增加的EndoMT已经在糖尿病性肾病和视网膜病变中描述，在这些细胞中促进EndoMT的相同因素在糖尿病性心脏中启动。
Figure 2 Myofibroblasts the central players in cardiac fibrogenesis. ECM: Extracellular matrix; EndoMT: Endothelial-mesenchymal transition; EPC: Endothelial progenitor cell.

sites (e.g., TGF β-Smad3) are also increased in the diabetic myocardium as the content of cardiac myofibroblasts is also increased.

**Endothelitis and endothelial progenitor cells**

Circulating endothelial progenitor cells (EPCs) normally participate in the process of new blood vessel formation and vascular repair. In the setting of cardiac ischaemia, the mobilisation of EPCs is thought to contribute to optimal remodelling. Elevated number and the function of EPCs is generally correlated with better endothelial function. Indeed, EPCs have been suggested as useful additional marker of endothelial function. In diabetes, functionality of EPCs is weakened, including impaired migration, mobilization, adhesion and homing, reduced ability to proliferate, differentiate and survive, leading to reduced reparative capacity. In addition, EPC numbers are paradoxically normal or sometime s reduced. In particular, EPC numbers also fall in patients with diabetic kidney disease, especially with increasing albuminuria or reducing renal function.

**Cross talk between endothelium and cardiomyocytes**

The endothelium not only regulates and redistributes regional blood flow. Endothelial cells also have significant paracrine effects to regulate regional function. For example, it is well established that vascular smooth muscle function is modified through the altered production of vasoactive substances by endothelial cells (e.g., NO). In addition, in the heart, diffusible factors released from the coronary and endocardial endothelium also modulate underlying cardiomyocyte contractility and remodelling. These factors include NO, prostaglandins, endothelins, interleukins, and other “angiocrine” small-molecules. For example, NO released from the endothelium stimulates an earlier onset of relaxation favouring diastolic filling. In co-culture experiments, endothelial cells modulate the contraction and relaxation of cardiomyocytes, and this is substantially altered by the induction of endothelial inflammation (e.g., pre-exposure to TNF-α or interleukin-1β). Consequently, the impact of impaired NO generation associated with endothelial dysfunction extends beyond simply changes in local blood flow to real-time cardiac dynamics.

The paracrine signals emerging from endothelitis also alters the perivascular environment to activate pathways that ultimately converge on converge on myocardial fibrosis. A quiescent endothelium releases factors that suppress fibrogenesis including bone morphogenetic protein 9 (BMP9), while an activated endothelium releases pro-fibrotic cytokines including TGF-β and IL-33, MCP-1, endothelin-1 (ET-1). In addition, paracrine and autocrine signalling of the renin-angiotensin-aldosterone system (RAAS), and its primary mediator Ang II, are known to have a direct influence on the progression of the atherosclerotic process, reactive ventricular hypertrophy, and myocardial fibrosis. Diabetes is classically associated with activation of the cardiac RAAS, at least partly through the development of endothelitis. Moreover, blockade of the RAAS in the setting of diabetes, using ACE inhibitors angiotensin receptor blockers or mineralocorticoid receptor blockade, has clear effects on vascular remodelling and myocardial fibrosis, over and above their effects on blood pressure.
The beating heart has only a limited capacity for energy substrate synthesis or storage, relying instead on blood flow and transit across the endothelium for its energy needs. Changes in metabolic status (e.g., feeding or fasting state) and therefore optimal substrate utilisation are communicated both to and from the vascular endothelium. Beyond regulating blood flow and the trans-endothelial supply of metabolic substrates, paracrine signals from the endothelium also have a major impact on cardiac metabolism, including NO, insulinotropic factors, growth factors and enzymes[4]. In addition, endothelial lipase (EL) activity appears to play an important role in liberating free fatty acids from high density lipoproteins to be used in cardiac metabolism, as genetic depletion of endothelial lipase results in heart failure due to reduced fatty acid uptake in the heart[31]. In cardiac hypertrophy, EL activity is increased, possibly to facilitate increased fat supply to the myocardium. Serum EL concentrations in human plasma are associated with circulating inflammatory markers, while plasma levels are increased in diabetes, heart failure and atherosclerosis. This increase in circulating EL may partly reflect the loss from endothelial sites associated with endothelitis that modulates cardiac metabolism and contributes to the long-term to dysfunction.

CONNECTING THE DOTS FROM THE LAB TO THE CLINIC PATIENT A FOCUS ON HFpEF

HFpEF is an evolving syndrome where observations have been predominately clinical and some pathophysiological connect. In the transition from Diabetes to HFpEF, knowing the canvas is large and will advance, we highlight 5 areas relevant to our regional context that the authors feel are worth exploring. Creating a clinical link for DM, DHD and finally HFpEF will be difficult, highlights the complexity of the syndrome, but is critical as more elements of the basic science map are revealed. In a recent review we discussed the importance of the primary step of confirming the diagnosis CHF, with solid proof, i.e. elevation of left ventricular end diastolic pressure (LVEDP). A rise in LVEDP in the absence of systolic impairment, is then the result of a complex interplay of diastolic phase that is unable to contribute (is impaired/ or failing) to overall cardiac output directly or through adequate counterregulatory compensation or the lack of it (dysfunction). A direction to approach this interplay has been published and we refer readers to Figure 1 in reference 2. From this complex canvas we extract several clinical observations and areas we feel relevant for further study (Figure 3). We break this down in an inflammatory context:

Inflammation: Being selective and finding where to focus in this vast area is important. For example, chronic sterile inflammation has key pathways triggered by dying cells such as IL-1α[32], suggests opportunities exist for identifying other key pathways.

Clinical scenario: (1) Acute Decompensated Heart Failure (ADHF) – is the drawing board to for clinical studies. Often patients present with CHF and are discharged after a short stay. Trials have predominately focused on relieving congestion. The future landscape should be greater forensic interrogation of molecular and clinical observations; (2) Risk factors – pregnancy and future risk of HFpEF, hypertension and metabolic syndromes suggest a haemodynamic connect. Aging is associated diastolic impairment on echocardiography although the clinical manifestation varies suggesting a more complex interaction[33][34]; (3) Obesity (flux) – is difficult to determine if it’s a risk factor, association, driver of cardiac decompensation (ADHF) or a combination. However rapid changes in weight in either direction can provide exponential clinical changes in symptoms; and (4) Secondary endorgan – Chronic renal impairment (CRI) and retention of protein bound uremic toxins (PBUT), which have robust pro-inflammatory properties but have been relatively immune to treatments[35].

Tissue/systems: Four arms the mechanical, cytoskeletal (structure), conduction and heart, the interconnectivity (hemodynamical and molecular) shape the clinical picture of HFpEF.

Pathophysiological changes: When tissue and systems are exposed to disease or altered state a series of changes occur that is initially transient then becomes permanent. This remodelling leads to heart failure but also feedback loops. In time an equilibrium sets in that changes baseline levels e.g., biomarkers like natriuretic peptides.
Questions: Based on points 1-4 here we need to devise how we examine these areas. Four pressing areas are needed: Firstly – a basic science program including animal models, omics and biobanks to that have close relationship with clinician and scientists; Secondly are diagnostic biomarkers, by understanding disease baseline and changes when under stress to help with bedside stress testing diagnosis and monitoring treatment response\(^{30}\); Finally as there are so more causative confounders and counterregulatory pathways identifying key pathways will help focus clinical questions.

In summary while the above list is superficial however the idea of creating flow loops is vital as HFpEF remains a syndrome at its infancy. Much is not known and observations and idea are still welcome additions to this science\(^{36-38}\).

**CONCLUSION**

There is an undeniable link between systemic inflammation and primary metabolic comorbidities including diabetes, obesity, obstructive sleep apnoea and secondary associations including aging, hypertension, lifestyle. These are all associated with endothelitis and the resulting vascular dysfunction is a “common soil” for atherogenesis and cardiac failure\(^{39,40}\). The cellular mechanism for inflammation in the subendothelial space that leads to atherogenesis and the inflammatory changes in the failing heart begins with (1) Dysfunctional endothelial changes that facilitate the recruitment of inflammatory cells; (2) Furthermore, increased barrier permeability, reduced thromboresistance, and altered paracrine signalling associated with endothelitis contributes to and compounds adverse vascular and cardiac remodelling in diabetes; and (3) In so far as, endothelitis is a driving force of progressive cardiac dysfunction in diabetes, then targeting microvascular dysfunction should provide benefits for patients with diabetes. The bench to bedside link can be seen when optimal glucose and blood pressure control have microvascular as well as macrovascular benefits, albeit largely when instituted early in the course of disease and continued for long periods of time (> 10 years). In addition, blockade of the RAAS in patients with a high cardiovascular risk or CHF is unequivocally associated with improved clinical outcomes, independent of blood pressure reduction, and over short trial intervals. The MICRO-HOPE study, treatment with ramipril was associated with a reduction in CHF hospitalisation and major acute coronary events. With increasing understanding of “diabetic endothelitis” and its contribution to HFpEF specifically, in the future a more direct targeting of endothelial dysfunction with therapies including anti-inflammatory therapies, oral nitrite/nitrate, guanylyl cyclase activators and phosphodiesterase inhibitors may prove useful. An improved understanding of these
REFERENCES


24. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X,
Diabetic endothelitis and HFpEF


Nanayakkara S, Haykovsky M, Mariani J, Van Empel V, Maeder MT, Vizi D, Kaye DM. Hemodynamic Profile of Patients With Heart Failure and Preserved Ejection Fraction Vary by Age. *J Am Heart Assoc* 2017; 6 [PMID: 28939710 DOI: 10.1161/JAHA.116.005434]


Di Paolo NC, Shayakhmetov DM. Interleukin 1α and the inflammatory process. *Nat Immuno* 2016; 17: 906-913 [PMID: 27434011 DOI: 10.1038/ni.3503]


